Targeting myeloid chemotaxis to reverse prostate cancer therapy resistanceChristina Guo, Johann S. de Bono, Ines Figueiredo et al.|Nature|2023Cited by 119
557P Binimetinib, pemetrexed (Pem) and cisplatin (Cis), followed by maintenance of Binimetinib and Pem in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations: The phase Ib SAKK 19/16 trialPatrizia Froesch, Martin Früh, Michael Mark et al.|Annals of Oncology|2020Cited by 1